222 BERKELEY STREET, BOSTON, MA
Annual Meeting of Stockholders Held; 64.1 Million Votes Cast
Investor Presentation
Reports First Quarter 2026 Financial Results and Business Update
Announces Changes to Board of Directors
Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment
Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity
Q1
FY 2025
Q3
Q2
FY 2023
Q2 amended
Registration Statement for Securities to be Offered to Employees
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities